"Weighing in" on synergy: Preclinical research on neurohormonal anti-obesity combinations

Brain Research

Volumn 1350, Issue , 2010, Pages 86-94

  Roth, Jonathan D ^a   Trevaskis, James L ^a   Turek, Victoria F ^a   Parkes, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Combination therapy; Leptin; Obesity; Synergy

Indexed keywords

ADIPOCYTOKINE; AMYLIN; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; LEPTIN; NEUROHORMONE; NEUROTRANSMITTER; PHENTERMINE; PRAMLINTIDE;

DRUG DOSE TITRATION; DRUG POTENTIATION; ENERGY BALANCE; FOOD INTAKE; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH BYPASS; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; COMBINED MODALITY THERAPY; HUMANS; ISLET AMYLOID POLYPEPTIDE; LEPTIN; OBESITY; WEIGHT LOSS;

EID: 77956176469     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.01.027     Document Type: Review

References (49)

1. L. Aronne, K. Fujioka, V. Aroda, K. Chen, A. Halseth, N.C. Kesty, C. Burns, C.W. Lush, and C. Weyer Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study J. Clin. Endocrinol. Metab. 92 2007 2977 2983
2. R.L. Batterham, M.A. Cowley, C.J. Small, H. Herzog, M.A. Cohen, C.L. Dakin, A.M. Wren, A.E. Brynes, M.J. Low, M.A. Ghatei, R.D. Cone, and S.R. Bloom Gut hormone PYY(3-36) physiologically inhibits food intake Nature 418 2002 650 654
3. R.L. Batterham, D.H. Ffytche, J.M. Rosenthal, F.O. Zelaya, G.J. Barker, D.J. Withers, and S.C. Williams PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans Nature 450 2007 106 109
4. S.C. Benoit, E.L. Air, K. Wilmer, P. Messerschmidt, K.M. Hodge, M.B. Jones, D.M. Eckstein, C.C. McOsker, R.J. Seeley, S.C. Woods, and R.J. Sheldon Two novel paradigms for the simultaneous assessment of conditioned taste aversion and food intake effects of anorexic agents Physiol. Behav. 79 2003 761 766
5. S. Bhavsar, J. Watkins, and A. Young Synergy between amylin and cholecystokinin for inhibition of food intake in mice Physiol. Behav. 64 1998 557 561
6. C.N. Boozer, R.L. Leibel, R.J. Love, M.C. Cha, and L.J. Aronne Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats Metabolism 50 2001 889 893
7. M. Chavez, R.J. Seeley, and S.C. Woods A comparison between effects of intraventricular insulin and intraperitoneal lithium chloride on three measures sensitive to emetic agents Behav. Neurosci. 109 1995 547 550
8. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
9. H.M. Connolly, J.L. Crary, M.D. McGoon, D.D. Hensrud, B.S. Edwards, W.D. Edwards, and H.V. Schaff Valvular heart disease associated with fenfluramine-phentermine N. Engl. J. Med. 337 1997 581 588
10. J.W. Day, N. Ottaway, J.T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen, D. Bruemmer, D.J. Drucker, N. Chaudhary, J. Holland, J. Hembree, W. Abplanalp, E. Grant, J. Ruehl, H. Wilson, H. Kirchner, S.H. Lockie, S. Hofmann, S.C. Woods, R. Nogueiras, P.T. Pfluger, D. Perez-Tilve, R. DiMarchi, and M.H. Tschop A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. 5 2009 749 757
11. R.W. Foltin, W.L. Woolverton, and C.R. Schuster Effects of psychomotor stimulants, alone and in pairs, on milk drinking in the rat after intraperitoneal and intragastric administration J. Pharmacol. Exp. Ther. 226 1983 411 418
12. R.W. Foltin, W.L. Woolverton, and C.R. Schuster The effect of d-amphetamine and haloperidol alone and in combination on milk drinking in rats Psychopharmacology (Berl.) 80 1983 342 344
13. K.M. Gadde, and D.B. Allison Combination therapy for obesity and metabolic disease Curr. Opin. Endocrinol. Diabetes Obes. 16 2009 353 358
14. K.M. Gadde, and D.B. Allison Combination pharmaceutical therapies for obesity Expert Opin. Pharmacother. 10 2009 921 925
15. I. Gantz, N. Erondu, M. Mallick, B. Musser, R. Krishna, W.K. Tanaka, K. Snyder, C. Stevens, M.A. Stroh, H. Zhu, J.A. Wagner, D.J. Macneil, S.B. Heymsfield, and J.M. Amatruda Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults J. Clin. Endocrinol. Metab. 92 2007 1754 1757
16. F.L. Greenway, M.J. Whitehouse, M. Guttadauria, J.W. Anderson, R.L. Atkinson, K. Fujioka, K.M. Gadde, A.K. Gupta, P. O'Neil, D. Schumacher, D. Smith, E. Dunayevich, G.D. Tollefson, E. Weber, and M.A. Cowley Rational design of a combination medication for the treatment of obesity Obesity 17 2009 30 39 (Silver Spring)
17. P.S. Grigson Conditioned taste aversions and drugs of abuse: a reinterpretation Behav. Neurosci. 111 1997 129 136
18. S.B. Heymsfield, A.S. Greenberg, K. Fujioka, R.M. Dixon, R. Kushner, T. Hunt, J.A. Lubina, J. Patane, B. Self, P. Hunt, and M. McCamish Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial JAMA 282 1999 1568 1575
19. J.O. Hill, and J.C. Peters Environmental contributions to the obesity epidemic Science 280 1998 1371 1374
20. P. Hollander, D.G. Maggs, J.A. Ruggles, M. Fineman, L. Shen, O.G. Kolterman, and C. Weyer Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients Obes. Res. 12 2004 661 668
21. C.J. Hukshorn, W.H. Saris, M.S. Westerterp-Plantenga, A.R. Farid, F.J. Smith, and L.A. Campfield Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men J. Clin. Endocrinol. Metab. 85 2000 4003 4009
22. J. Jordan, F.L. Greenway, L.A. Leiter, Z. Li, P. Jacobson, K. Murphy, J. Hill, L. Kler, and R.P. Aftring Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients Clin. Pharmacol. Ther. 83 2008 281 287
23. H.R. Kissileff, F.X. Pi-Sunyer, J. Thornton, and G.P. Smith C-terminal octapeptide of cholecystokinin decreases food intake in man Am. J. Clin. Nutr. 34 1981 154 160
24. C.W. le Roux, R.L. Batterham, S.J. Aylwin, M. Patterson, C.M. Borg, K.J. Wynne, A. Kent, R.P. Vincent, J. Gardiner, M.A. Ghatei, and S.R. Bloom Attenuated peptide YY release in obese subjects is associated with reduced satiety Endocrinology 147 2006 3 8
25. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, L. Zhu, X. Du, A. Petrov, M.E. Lassman, G. Jiang, F. Liu, C. Miller, L.M. Tota, G. Zhou, X. Zhang, M.M. Sountis, A. Santoprete, E. Capito, G.G. Chicchi, N. Thornberry, E. Bianchi, A. Pessi, D.J. Marsh, and R. SinhaRoy Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 58 2009 2258 2266
26. E. Ravussin, S.R. Smith, J.A. Mitchell, R. Shringarpure, K. Shan, H. Maier, J.E. Koda, and C. Weyer Enhanced weight loss with pramlintide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring) 17 2009 1736 1743
27. L.M. Redman, L.K. Heilbronn, C.K. Martin, L. de Jonge, D.A. Williamson, J.P. Delany, and E. Ravussin Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss PLoS ONE 4 2009 e4377
28. J. Rodin, D. Schank, and R. Striegel-Moore Psychological features of obesity Med. Clin. North Am. 73 1989 47 66
29. M. Rosenbaum, R. Goldsmith, D. Bloomfield, A. Magnano, L. Weimer, S. Heymsfield, D. Gallagher, L. Mayer, E. Murphy, and R.L. Leibel Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight J. Clin. Invest. 115 2005 3579 3586
30. M. Rosenbaum, M. Sy, K. Pavlovich, R.L. Leibel, and J. Hirsch Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli J. Clin. Invest. 118 2008 2583 2591
31. J.D. Roth, and N.E. Rowland Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy? Eur. J. Pharmacol. 373 1999 127 134
32. J.D. Roth, H. Hughes, E. Kendall, A.D. Baron, and C.M. Anderson Anti-obesity effects of the β-cell hormone amylin in diet induced obese rats: effects on food intake, body weight, composition, energy expenditure and gene expression Endocrinology 147 2006 5855 5864
33. J.D. Roth, T. Coffey, C.M. Jodka, H. Maier, J.R. Athanacio, C.M. Mack, C. Weyer, and D.G. Parkes Combination therapy with amylin and peptide YY 3-36 in obese rodents: anorexigenic synergy and weight loss additivity Endocrinology 148 2007 6054 6061
34. J.D. Roth, B.L. Roland, R.L. Cole, J.L. Trevaskis, C. Weyer, J.E. Koda, C.M. Anderson, D.G. Parkes, and A.D. Baron Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proc. Natl. Acad. Sci. USA 105 2008 7257 7262
35. J.D. Roth, J.L. Trevaskis, J. Wilson, C. Lei, J. Athanacio, C. Mack, N.C. Kesty, T. Coffey, C. Weyer, and D.G. Parkes Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats Int. J. Obes. (Lond.) 32 2008 1201 1210
36. N.E. Rowland, M. Marshall, and J.D. Roth Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats Psychopharmacology (Berl.) 149 2000 77 83
37. N.E. Rowland, M. Mukherjee, and K. Robertson Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats Psychopharmacology (Berl.) 159 2001 111 116
38. J.K. Rowlett, and W.L. Woolverton Evaluation of the effects of cocaine, heroin and naltrexone, alone and in combination, on milk drinking in rats Behav. Pharmacol. 6 1995 821 829
39. S.R. Smith, J.E. Blundell, C. Burns, C. Ellero, B.E. Schroeder, N.C. Kesty, K.S. Chen, A.E. Halseth, C.W. Lush, and C. Weyer Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study Am. J. Physiol. Endocrinol. Metab. 293 2007 E620 E627
40. S.R. Smith, L.J. Aronne, C.M. Burns, N.C. Kesty, A.E. Halseth, and C. Weyer Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes Care 31 2008 1816 1823
41. R.J. Tallarida, and R.B. Raffa Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram Life Sci. 58 1996 PL 23 PL 28
42. R.J. Tallarida Drug synergism: its detection and applications J. Pharmacol. Exp. Ther. 298 2001 865 872
43. J.L. Trevaskis, T. Coffey, R. Cole, C. Lei, C. Wittmer, B. Walsh, C. Weyer, J. Koda, A.D. Baron, D.G. Parkes, and J.D. Roth Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms Endocrinology 149 2008 5679 5687
44. J.L. Trevaskis, C. Lei, J.E. Koda, C. Weyer, D.G. Parkes, and J.D. Roth Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats Obesity (Silver Spring) 18 2009 21 26
45. V.F. Turek, J.L. Trevaskis, B.E. Levin, A.A. Dunn-Meynell, B. Irani, G. Gu, C. Wittmer, P.S. Griffin, C. Vu, D.G. Parkes, and J.D. Roth Mechanisms of Amylin/Leptin Synergy in Rodent Models Endocrinology 151 2009 143 152
46. M. Weintraub, P.R. Sundaresan, M. Madan, B. Schuster, A. Balder, L. Lasagna, and C. Cox Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo Clin. Pharmacol. Ther. 51 1992 586 594
47. P.J. Wellman, S. Tow, and L. McMahon Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats Pharmacol. Biochem. Behav. 50 1995 287 291
48. S.C. Woods, D.P. Figlewicz, L. Madden, D. Porte Jr., A.J. Sipols, and R.J. Seeley NPY and food intake: discrepancies in the model Regul. Pept. 75-76 1998 403 408
49. Y.P. Zverev Effects of caloric deprivation and satiety on sensitivity of the gustatory system BMC Neurosci. 5 2004 5